Pancreatic-cancer-patient tumor specimens were initially established subcutaneously in NOD/SCID mice immediately after surgery. The patient tumors were then harvested from NOD/SCID mice and passaged orthotopically in transgenic nude mice ubiquitously expressing red fluorescent protein (RFP). The primary patient tumors acquired RFP-expressing stroma. The RFP-expressing stroma included cancerassociated fibroblasts (CAFs) and tumor-associated macrophages (TAMs). Further passage to transgenic nude mice ubiquitously expressing green fluorescent protein (GFP) resulted in tumors that acquired GFP stroma in addition to their RFP stroma, including CAFs and TAMs as well as blood vessels. The RFP stroma persisted in the tumors growing in the GFP mice. Further passage to transgenic nude mice ubiquitously expressing cyan fluorescent protein (CFP) resulted in tumors acquiring CFP stroma in addition to persisting RFP and GFP stroma, including RFP-and GFP-expressing CAFs, TAMs and blood vessels. This model can be used to image progression of patient pancreatic tumors and to visually target stroma as well as cancer cells and to individualize patient therapy.
T he athymic, T-cell-deficient, nude mouse has made a very important contribution to cancer research in that it enabled the systemic serial transplantation of human tumors and cell lines [Rygaard and Povlsen, 1969] . Our laboratory pioneered surgical orthotopic implantation (SOI) metastatic nude-mouse models of patient tumor specimens in the early 1990s [Fu et al., 1991 [Fu et al., , 1992 . These orthotopic mouse models of patient tumors are more patientlike, especially with regard to metastasis, than ectopic subcutaneous models [Rygaard and Povlsen, 1969; Pickard et al., 1975; Giovanella et al., 1978; Nowak et al., 1978; Bailey et al., 1980; Selby et al., 1980; Fiebig et al., 1984 Fiebig et al., , 1987 Sharkey and Fogh, 1984; Steel, 1984; Hwang et al., 2003; Embuscado et al., 2005; Rubio-Viqueira et al., 2006; Garber, 2007; Talmadge et al., 2007; Bertotti et al., 2011] . In our initial development of SOI nude mouse models of patient tumors, we achieved take rates of 65% for colon cancer [Fu et al., 1991] and 100% for pancreatic cancer. Subsequently, the NOD/SCID mouse, was developed [Shultz et al., 1995] . This mouse is deficient in T-, B-and NK cells and allows for higher take rates of patient tumors including 87% for colorectal cancer liver metastasis [Bertotti et al., 2011] . Patient pancreatic tumors have been transplanted to NOD-SCID mice at high frequency [Kim et al., 2009 [Kim et al., , 2011 . However, these models are limited with regard to studying the tumor microenvironment as well as imaging.
The use of fluorescent proteins for imaging in vivo was pioneered by out laboratory and has been particularly useful to study tumor growth and progression [Hoffman and Yang, 2006a, b; Hoffman, 2005] . With the use of multiple colored fluorescent proteins, we developed imaging of the tumor microenvironment (TME) by color-coding cancer and stromal cells [Yang et al., 2003 [Yang et al., , 2004 [Yang et al., , 2007 [Yang et al., , 2009 Hoffman and Yang, 2006b; Suetsugu et al., 2011 Suetsugu et al., , 2012 . With the use of color-coded imaging technology, we have previously demonstrated the essential role of tumor-associated host cells in tumor progression and metastasis .
The present study utilizes a pallet of multicolored fluorescent proteins to image the recruitment over time of stromal cells, including cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) by pancreatic-cancer-patient tumors grown orthotopically in three types of transgenic nude mice, each expressing a different color fluorescent protein (Yang et al., 2004; Yang et al., 2009; Tran Cao et al., 2009 ). This study allows for the first time the visualization and demonstration of the persistence of the TME of patient tumors as well and their fluorescence imaging in mouse models.
MATERIALS AND METHODS

SPECIMEN COLLECTION
All patients provided informed consent and samples were procured and the study was conducted under the approval of the Institutional Review Board of the MD Anderson Cancer Center.
GFP, RFP, AND CFP MICE
Transgenic nude C57/B6-GFP, RFP, and CFP mice were obtained from AntiCancer, Inc. (San Diego, CA). These transgenic nude mice express the fluorescent protein gene under the control of the chicken b-actin promoter and cytomegalovirus enhancer. Most of the tissues from these transgenic mice, with the exception of erythrocytes and hair, fluoresce under proper excitation light [Yang et al., 2004; Tran Cao et al., 2009; Yang et al., 2009] .
ANIMAL CARE
The transgenic nude mice were bred and maintained in a HEPAfiltered environment at AntiCancer, Inc. with cages, food, water, and bedding sterilized by autoclaving. All surgical procedures and imaging were performed with the animals anesthetized by intramuscular injection of a ketamine mixture. All animal studies were conducted in accordance with the principles of and procedures outlined in the NIH guide for the care and use of laboratory animals under assurance number A3873-1.
ESTABLISHMENT OF TUMORGRAFT MODEL (F1) OF PANCREATIC CANCER PATIENT TUMORS
Pancreas cancer patient tumor tissue was obtained at surgery and cut into 3-mm 3 fragments and transplanted subcutaneously in NOD/ SCID mice (Kim et al., 2009 (Kim et al., , 2011 .
ORTHOTOPIC TUMORGRAFT (F2) OF PANCREATIC CANCER PATIENT TUMORS IN TRANSGENIC RFP NUDE MICE
The F1 tumors from NOD/SCID mice were harvested and cut into 3-mm 3 fragments and transplanted orthotopically [Hoffman, 1999] in 6-week-old transgenic nude RFP mice (Yang et al., 2009) (F2 model) .
ORTHOTOPIC TUMORGRAFT (F3) OF PANCREATIC CANCER PATIENT TUMORS IN TRANSGENIC GFP NUDE MICE
The F2 tumors were harvested from the RFP nude mice and were cut into 3-mm 3 fragments and transplanted orthotopically [Hoffman, 1999] in 6-week-old transgenic nude GFP mice (Yang et al., 2009) (F3 model) .
ORTHOTOPIC TUMORGRAFT (F4) OF PANCREATIC CANCER PATIENT TUMORS IN TRANSGENIC CFP NUDE MICE
The F3 tumors were harvested from the GFP nude mice and cut into 3-mm 3 fragments and transplanted orthotopically [Hoffman, 1999] in 6-week-old transgenic nude CFP mice (Tran Cao et al., 2009 ) (F4 model).
TUMOR IMAGING
The OV100 variable magnification Small Animal Imaging System [Yamauchi et al., 2006] , the FV1000 confocal microscope [Uchugonova et al., 2011] , and the MVX10 long-working distance fluorescence dissecting microscope [Kimura et al., 2010] , all from Olympus Corp. (Tokyo, Japan), were used in this study.
RESULTS AND DISCUSSION ENGRAFTMENT OF PATIENT TUMORS (F1) IN NOD/SCID MOUSE
A flow diagram experimental protocols is shown (Fig. 1A ). Human pancreatic-cancer patient tumors were initially transplanted subcutaneously in NOD/SCID mice. Tumors were detected by day-30. Tumors were harvested from the NOD/SCID mice.
RFP HOST STROMAL CELLS INFILTRATE ORTHOTOPIC PANCREATIC CANCER TUMORGRAFTS (F2)
The harvested human pancreatic cancer patient tumors from the NOD/SCID mice were transplanted orthotopically in 6-week-old transgenic RFP nude mice (F2 model). After 30 days, tumors were imaged using the OV100 (Fig. 1B) . The RFP stromal cells from the RFP host mice formed a capsule around the F2 tumor ( Fig. 1B) and infiltrated into the central part of the tumor as well (Fig. 1C ). RFP-expressing TAMs could be visualized in the tumor (Fig. 1D ).
GFP HOST STROMAL CELLS INFILTRATE THE ORTHOTOPIC PANCREATIC CANCER TUMORGRAFTS TO FORM A TWO-COLOR STROMA MODEL (F3)
The F2 tumor was harvested at day-30, cut into 3-mm 3 pieces, and transplanted orthotopically in 6-week-old transgenic GFP nude mice (F3 model). After 30 days, tumors were imaged with the OV100 (Fig. 1E) . The F2 tumor spread on the host GFP pancreas (Fig. 1F) . After 56 days, tumors were removed from the GFP nude mice. The human pancreatic-cancer-patient tumors contained both RFP and GFP stromal cells (Fig. 1G) . The RFP stromal cells still persisted after passage in the F3 tumorgraft. Under confocal microscopy with the FV1000, RFP and GFP stromal cells were clearly visualized in the tumor (Fig. 1H ). GFP and RFP CAFs and TAMs were visualized including in the central part of the tumor (Fig. 1H-J) .
CFP HOST STROMAL CELLS INFILTRATE ORTHOTOPIC PANCREATIC CANCER TUMORGRAFTS TO FORM A THREE-COLOR STROMA MODEL (F4)
F3 tumors were harvested at day-56 and transplanted orthotopically in 6-week-old nude CFP mice (F4 model). After 30 days, F4 tumors were observed with the MVX10 long-working-distance fluorescence microscope ( Fig. 2A,B) . The excised F4 tumor was also observed with the FV1000 confocal microscope (Fig. 2C-F) . RFP-, GFP-, and CFP-expressing stromal cells were observed in the human pancreatic-cancer patient tumor (Fig. 2C) . The RFP stroma persisted after two passages and GFP stroma persisted after one passage in the F4 model in CFP mice. RFP TAMs and CAFs (Fig. 2D,F) and GFP blood vessels (Fig. 2D,E) still persisted in the human pancreaticcancer patient tumor after 2 and 1 passages, respectively (Fig. 2F) .
We have thus demonstrated a new mouse model of cancer-patient tumors, whereby stromal elements can be imaged using a pallet of multi-color fluorescent proteins. The fluorescent stroma persisted for at least two passages in the tumors growing in the transgenic mice, indicating the intimacy of cancer cells and stroma. The survival of stroma after transplantation was previously suggested [Duda et al., 2004] . The results of the present study demonstrate the serial transplantability of stroma. For example from the RFP mice, TAMs and CAFs persisted from F2 to F4, suggesting they may be proliferating along with the cancer cells in the tumor. From the GFP mice, TAMs and CAFs and blood vessels were found in the tumor and persisted to F4. The CFP mice contributed mostly CAFs to the tumor. The fluorescent stroma allow the entire tumor to be imaged as well. Both standard and novel cancer-and stroma-targeting agents can be tested in this model and can be used for individualized therapy of cancer patients.
The new models described in this report offer many opportunities. For example, cell lines can be established from the tumors with fluorescent stroma and the role of stroma in cell line establishment can be imaged longitudinally.
The stromal cells of each fluorescent color can be isolated by fluorescence-activated cell sorting (FACS) to further characterize them.
Since the stroma carry genes for fluorescent proteins, it may be possible to observe gene transfer from stromal cells to the cancer cells. We have previously taken advantage of differential fluorescent protein expression in cancer cells to demonstrate gene transfer between cancer cells in vivo [Glinsky et al., 2006; Tome et al., 2009 ].
It should also be possible to determine if some of the fluorescent stromal cells are derived from tissue-specific stem cells or mesenchymal stem cells.
One of the most exciting opportunities directly inspired by observations in the current study and enabled by the availability of the color-coded panel of hosts, would be the analysis of the role, requirements, and contribution of host stroma to metastatic initiation and progression.
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The modern arsenal of methodologies features computational analyses to assess, link and integrate large bodies of data. Genome-wide analyses of gene expression are widely used to ask how cancers, including hepatocellular carcinoma (HCC), compromise normal cellular functions, to determine signifi cant pathways and specifi c factors active in cause or effect, and to develop gene signatures that may classify sub-types of tumors. The remarkable ability of liver to regenerate tissue mass and maintain metabolic function, even when highly compromised by toxins, injury or disease, parallels HCC in multiple ways: induced infl ammation triggers proliferation, hyperplasia, vasculogenesis and architectural restructuring. In this "Prospects" Article, Coban and Barton integrate gene expression profi ling of differentially regulated HCC-associated genes, fi ltered by comparisons of human HCC, mouse models of HCC and normal tissue, with profi les over a time course o f liver regeneration. Hierarchal clustering reveals distinct groups of HCC-associated genes, up-regulated to function in cell cycle or down-regulated in metabolic functions, which segregate at specifi c phases of regeneration. These and other integrative analyses, expanded to a growing collection of comprehensive datasets, will offer new understanding of molecular mechanisms, held in common or unique to HCC or regeneration, and suggest new biomarkers, therapeutic targets or strategies for disease treatment.
Integration and Distillation: Global Comparisons of Liver Regeneration and HCC
Zeynep Coban and Michelle Craig Barton
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ACCEPTED MANUSCRIPT ONLINE 17 FEBRUARY 2012 Cancer patient tumors have been grown in nude mouse models since 1969, but they are usually grown subcutaneously where they do not metastasize and are not readily imageable. Suetsugu et al. report in this issue on glowing pancreatic cancer patient tumors growing in nude mice. The patient tumors were fi rst established in SCID-NOD mice, and then serially orthotopically implanted to three types of glowing transgenic nude mice: those expressing red fl uorescent protein (RFP); those expressing green fl uorescent protein (GFP); and fi nally to cyan fl uorescent protein (CFP)-expressing transgenic nude mice. After growth and passage in the different colored transgenic nude mice, the patient tumors stably retained stroma of three colors, making the whole tumor brilliantly fl uorescent. Confocal microscopy of the patient tumors after growth in 3 types of colored transgenic mice, visualized cancer-associated fi broblasts (CAFs), tumor associated macrophages (TAMs), and other stromal cells glowing either in RFP, GFP, or CFP, whose role in patient tumor progression can now be visualized. The glowing patient tumors will be ideal for noninvasive imaging of their growth, progression, and metatasis in non-transgenic nude mice, and will be a powerful tool for screening individualized patient therapeutics.
Making Patient Tumors Glow in Mice
Atsushi Suetsugu, Matthew Katz, Jason Fleming, Mark Truty, Ryan Thomas, Hisataka Moriwaki, Michael Bouvet, Shigetoyo Saji, and Robert M. Hoffman 
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ACCEPTED MANUSCRIPT ONLINE 14 FEBRUARY 2012 vii A long-standing puzzle in understanding X-linked hypophosphatemic rickets (XLH) has been whether the loss of Phex (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) protein in osteoblasts leads directly to undermineralization of the bone matrix or whether undermineralization is a secondary effect following from renally-induced hypophosphatemia and/or changes in other serum factors. Increasing evidence indicates a critical role for Runx2 in a variety of cancers, including those originating from prostate and breast epithelia. While Runx2 was originally identifi ed as a master transcriptional regulator of osteoblast maturation, its ectopic expression in cancer cells induces the expression of various cancer-related genes, including MMP9, SDF-1, CSF2, and IL6. Using prostate cancer cells that conditionally expressed Runx2, Purcell et al. established G9a, a histone methyltransferase, as a novel coregulator for Runx2-regulated gene expression. G9a binds to Runx2 in cultured cells and in cell-free conditions, and G9a is recruited to Runx2 binding sites on chromatin in a Runx2-dependent manner. Although G9a has been well characterized as a corepressor of gene expression, Purcell et al. showed that G9a contributes positively to Runx2-mediated expression of some genes, while limiting Runx2-mediated expression of other genes. Given the fact that both G9a and Runx2 are expressed by prostate as well as other metastatic cancer cells, these studies assert an important functional role for their crosstalk to regulate disease progression.
